Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 14, 2024 16:05 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
July 30, 2024 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024 08:00 ET
|
Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET
|
Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 14, 2023 17:50 ET
|
Genelux Corporation
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents...
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...